BusinessMyriad to Announce Fiscal Second-Quarter 2018 Financial Results on February 6, 2018By Nasdaq OMXJan 25, 2018, 12:05 PM UTC
BusinessFibrocell to Present at Phacilitate Cell and Gene Therapy World 2018By Nasdaq OMXJan 24, 2018, 1:01 PM UTC
BusinessMyriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations for Hereditary Prostate CancerBy Nasdaq OMXJan 22, 2018, 12:05 PM UTC
BusinessTurnkey Capital Inc. Signs Agreement with Palm Beach Integrative Medicine, Leases Medical Facility and Opens its First Practice that Blends Integrative and Functional Medicine with Medical Cannabis Certification Support and CareBy Nasdaq OMXJan 19, 2018, 1:00 PM UTC
BusinessPhase 1b/2 Study of Margetuximab in Combination with Pembrolizumab Presented at 2018 ASCO Gastrointestinal Cancers SymposiumBy Nasdaq OMXJan 18, 2018, 7:00 PM UTC
BusinessArbutus Announces Closing of the Second Tranche of a $116M Strategic Investment from Roivant SciencesBy Nasdaq OMXJan 16, 2018, 1:30 PM UTC
BusinessMyriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Metastatic Breast CancerBy Nasdaq OMXJan 12, 2018, 4:16 PM UTC
